Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide is a once-weekly injectable weight loss medication that works differently from older GLP-1 medicines — it activates two gut-hormone receptors, GIP and GLP-1, rather than one. In clinical trials, it produced average body-weight reductions of around 20–21% at the highest dose over 72 weeks, making it the most effective licensed weight loss injection currently available in the UK. Like all prescription-only weight loss medicines, it requires clinical assessment before a prescriber can approve it for you. If you're exploring whether tirzepatide weight loss injections could be right for you, this page covers how the injection works, what using it actually involves week to week, and what the evidence says.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people have heard of GLP-1 receptor agonists, the class that includes semaglutide. If you want a thorough grounding in how it all works, our page on the weight loss pen tirzepatide covers the science and the practicalities in one place. Tirzepatide belongs to that class but adds a second mechanism: it also activates GIP receptors, which play a separate role in appetite regulation and energy metabolism. Activating both pathways together appears to produce a stronger and more sustained reduction in appetite than either pathway alone, alongside the slower gastric emptying that makes meals feel satisfying for longer.
The practical result is that most people on tirzepatide eat considerably less without feeling deprived, appetite shifts rather than being suppressed by willpower. In SURMOUNT-1, the pivotal phase-3 trial published in the New England Journal of Medicine, participants on 15 mg lost an average of around 20–21% of body weight over 72 weeks. That's a figure that sits above anything a single-agonist injection achieved in equivalent trial conditions, and NICE's appraisal of tirzepatide acknowledged the indirect comparison when recommending it for NHS use.
The injection itself does not burn fat directly. It works through hormonal signalling that reshapes how hungry you feel and how quickly your stomach empties. Diet and physical activity remain part of the picture, the medicine creates the conditions for change; the change still happens through a calorie deficit.
The KwikPen is pre-filled and pre-set to the correct dose. You don't draw up a syringe or adjust a dial, you attach a needle, choose your injection site, and press. A question our prescribers hear most weeks is whether self-injection is difficult. For the vast majority of people it becomes routine within the first couple of uses.
You choose from three sites: abdomen, thigh or upper arm. Rotating within and between those areas reduces the chance of skin irritation or changes in absorption at a single spot. Injecting into the same patch repeatedly is the most common technique mistake, so varying the site matters more than most people expect. If you want to understand exactly what each weekly injection involves, our tirzepatide injection page walks through the full process in detail.
The pen is kept refrigerated between 2 °C and 8 °C. There is a limited window for storing it at room temperature, the exact duration is in the Patient Information Leaflet that comes with your medicine, and that's the figure to follow rather than any general estimate. Used needles go into a sharps container and are never recapped; a 1-litre sharps bin is a practical accessory to have to hand from the start.
The UK licence covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone doesn't settle the question, a prescriber looks at medical history, current medicines, and whether there are conditions that make tirzepatide unsuitable.
Tirzepatide is not recommended during pregnancy, breastfeeding or if you're actively trying to conceive. It isn't licensed for anyone under 18. People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, or certain gastrointestinal conditions, need a careful prescriber discussion before starting. The NHS tirzepatide medicines page covers the full contraindications list in plain language and is worth reading alongside any consultation.
NICE recommended tirzepatide for NHS use in December 2024 (TA1026), with specific BMI and comorbidity criteria that are being phased in over several years. Private prescriptions through a GPhC-registered pharmacy like ours follow the licensed criteria and require the same clinical assessment, the threshold for getting a prescription is the medicine's licence, not a lower bar. You can read more about the wider range of weight loss treatment options we offer if you're still at the comparing stage.
Gastrointestinal symptoms are the most common: nausea, loose stools, constipation, indigestion and burping each appear in a meaningful proportion of users, particularly in the early weeks or after a dose increase. For most people these settle as the body adjusts, and starting at 2.5 mg rather than a therapeutic dose exists precisely to reduce how pronounced they are during the adjustment phase.
Fatigue, headache and dizziness are reported less frequently but are worth knowing about. Injection-site reactions (minor redness or itching) tend to ease with good rotation technique. More rarely, tirzepatide can affect the gallbladder, and in January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known but infrequent risk: severe stomach pain that radiates toward the back, with or without vomiting, is a reason to seek medical attention the same day rather than wait. Any suspected side effects can be reported through the MHRA's Yellow Card scheme.
If you are on oral contraceptives, NHS guidance recommends adding a barrier method for the first four weeks of tirzepatide and for four weeks after each dose increase, as the injection may slow pill absorption. Women on oral HRT may want to discuss transdermal alternatives with their doctor for the same reason. These are conversations a prescriber will raise at the right point, and if you're weighing up branded versus unbranded options, our Mounjaro injection page explains how that version of the medicine works and what to expect week to week. You can also find practical guidance on how to use tirzepatide for weight loss, including a detailed look at how to take tirzepatide for weight loss, covering dosing schedules, injection timing, and what to do if you miss a dose.
When you're ready to discuss whether tirzepatide is clinically suitable for you, start your free consultation and a GPhC-registered prescriber will review your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.